Pyrimethamine 12.5 mg/ML / sulfadiazine 250 mg/ML [Rebalance]
RxNorm 1309304

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1309304 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: pyrimethamine 12.5 mg/ML / sulfadiazine 250 mg/ML [Rebalance].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Pyrimethamine 12.5 mg/ML / sulfadiazine 250 mg/ML [Rebalance]
AUI:12302885
View
TMSY
Pyrimethamine 12.5 mg/ML / sulfADIAZINE 250 mg/ML [Rebalance]
AUI:12378067
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDC

Semantic Branded Drug Component (SBDC):
Pyrimethamine 12.5 mg/ML / sulfadiazine 250 mg/ML [Rebalance]
(Atom ID: 12302885)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
pyrimethamine 12.5 MG/ML / sulfadiazine 250 MG/ML [Rebalance]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1309304
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12302885
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
1309304
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
TMSY

Tall Man Lettering Synonym (TMSY):
Pyrimethamine 12.5 mg/ML / sulfADIAZINE 250 mg/ML [Rebalance]
(Atom ID: 12378067)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
pyrimethamine 12.5 MG/ML / sulfADIAZINE 250 MG/ML [Rebalance]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1309304
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12378067
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
1309304
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.